Variable | N = 976 | P | |
---|---|---|---|
Recurrence (718) | No Recurrence (258) | Â | |
Female(%) | 266 (37.0%) | 111 (43.0%) | 0.091 |
Age (y, mean ± SD) | 62.5(±8.85) | 62.7(±9.38) | 0.638 |
WBC(a10^9/L, mean ± SD) | 6.0(±2.08) | 6.0(±2.15) | 0.234 |
Neutrophil(a10^9/L, mean ± SD) | 6.3(±12.11) | 4.3(±5.41) | 0.006 |
Lymphocyte(a10^9/L, mean ± SD) | 1.5(±0.64) | 1.5(±0.63) | 0.804 |
Monocyte(a10^9/L, mean ± SD) | 0.4(±0.34) | 0.5(±0.39) | 0.862 |
RBC(a10^12/L, mean ± SD) | 4.2(±0.56) | 4.1(±0.52) | 0.012 |
Hemoglobin(g/L, mean ± SD) | 128.6(±16.71) | 126.4(±16.44) | 0.086 |
Albumin(g/L, mean ± SD) | 38.9(±5.33) | 39.5(±5.01) | 0.076 |
LMR | 4.2(±5.65) | 3.9(±1.88) | 0.229 |
PLR | 155.8(±85.15) | 151.8(±85.08) | 0.409 |
NLR | 5.1(±10.84) | 3.4(±4.97) | 0.034 |
SIRI | 2.3(±4.75) | 1.7(±3.31) | 0.026 |
CA199 (U/mL, median with IQR) | 166.3 (44.35–554.60) | 112.7 (29.0–288.9) | < 0.0001 |
CA125(U/mL, median with IQR) | 16.8 (10.9–29.6) | 14.9 (10.4–23.2) | 0.012 |
CEA (ng/mL, median with IQR) | 3.5 (2.1–6.3) | 3.1 (1.9–4.8) | 0.016 |
Borderline resectable | 178 (24.8%) | 48 (18.6%) | 0.043 |
Tumor size (cm) | 3.0 (2.5–4.0) | 3 (2.0–3.5) | < 0.0001 |
Operation | 0.943 | ||
 Pancreaticduodenectomy | 468 (65.2%) | 170 (65.9%) |  |
 Distal pancreatectomy | 216 (30.1%) | 75 (29.1%) |  |
 Total pancreatectomy | 34 (4.7%) | 13 (5.0%) |  |
 Vascular resection | 113 (15.7%) | 40 (15.5%) | < 0.0001 |
 R0 resection | 636 (88.6%) | 244 (94.6%) | 0.006 |
Tumor differentiation | 0.006 | ||
 Well-moderate | 267 (37.2%) | 121 (46.9%) |  |
 Poor | 451 (62.8%) | 137 (53.1%) |  |
 Margin | 1.0 (0.6–2.0) | 1.5 (0.7–2.0) | 0.064 |
AJCC T-stage | < 0.0001 | ||
 T1–2 | 504 (70.2%) | 218 (84.5%) |  |
 T3–4 | 214 (29.8%) | 40 (15.5%) |  |
AJCC N-stage | < 0.0001 | ||
 0 | 315 (43.9%) | 163 (63.2%) |  |
 1 | 301 (41.9%) | 79 (30.6%) |  |
 2 | 102 (14.2%) | 16 (6.2%) |  |
 LNM | 403 (56.1%) | 95 (36.8%) | < 0.0001 |
 Number of LNM | 1 (0–2) | 0 (0–1) | < 0.0001 |
 Positive lymph node ratio | 0.06 (0–0.17) | 0 (0–0.08) | < 0.0001 |
 Perineural invasion | 690 (96.1%) | 238 (92.2%) | 0.014 |
AJCC stage | < 0.0001 | ||
  ≤ 2A | 291 (40.5%) | 157 (60.9%) |  |
 >2A | 427 (59.5%) | 101 (39.1%) |  |
Complications | 0.085 | ||
  < 3 | 606 (84.4%) | 209 (81.0%) |  |
  ≥ 3 | 26 (3.6%) | 16 (6.2%) |  |
POPF | 0.638 | ||
 Grade B/C POPF | 98 (13.6%) | 36 (14.0%) |  |
 Biochemical leak | 316 (44.0%) | 117 (45.3%) |  |
 Adjuvant chemotherapy | 499 (69.5%) | 174 (67.4%) | 0.057 |
 Gemcitabine | 71 (9.9%) | 13 (5.0%) |  |
 S-1 or Capecitabine | 44 (6.1%) | 14 (5.4%) |  |
 Combined a | 384 (53.5%) | 147 (57.0%) |  |
 OS | 15.7 (10.0–23.4) | 17.9 (11.3–36.0) | < 0.0001 |